Summary
The miGut-Health consortium aims to develop a personalized blueprint of intestinal health to predict and prevent inflammatory bowel disease. The overall goal is to deliver interdisciplinary solutions (molecular, nutritional, eHealth and patient engagement/empowerment level) for health promotion and disease prevention that would enable active patient engagement in health and self-care management.
Taking on this mission, miGut-Health pursues the following strategic goals:
- To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identification of actionable biomarkers, risk and health promoting factors linked to health-to-disease transition in the general population, IBD high risk persons, as well as IBD patients.
- To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.
- To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free diet) and its impact on intestinal inflammation in IBD patients and high-risk individuals.
- To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.
- To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.
- To implement a patient-centered approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population as well as tools for health-care professionals.
Taking on this mission, miGut-Health pursues the following strategic goals:
- To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identification of actionable biomarkers, risk and health promoting factors linked to health-to-disease transition in the general population, IBD high risk persons, as well as IBD patients.
- To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.
- To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free diet) and its impact on intestinal inflammation in IBD patients and high-risk individuals.
- To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.
- To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.
- To implement a patient-centered approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population as well as tools for health-care professionals.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101095470 |
| Start date: | 01-01-2023 |
| End date: | 31-12-2026 |
| Total budget - Public funding: | 7 131 243,75 Euro - 7 126 243,00 Euro |
Cordis data
Original description
The miGut-Health consortium aims to develop a personalized blueprint of intestinal health to predict and prevent inflammatory bowel disease. The overall goal is to deliver interdisciplinary solutions (molecular, nutritional, eHealth and patient engagement/empowerment level) for health promotion and disease prevention that would enable active patient engagement in health and self-care management.Taking on this mission, miGut-Health pursues the following strategic goals:
- To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identification of actionable biomarkers, risk and health promoting factors linked to health-to-disease transition in the general population, IBD high risk persons, as well as IBD patients.
- To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.
- To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free diet) and its impact on intestinal inflammation in IBD patients and high-risk individuals.
- To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.
- To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.
- To implement a patient-centered approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population as well as tools for health-care professionals.
Status
SIGNEDCall topic
HORIZON-HLTH-2022-STAYHLTH-02-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (Coördinator)
-
| ACADEMISCH ZIEKENHUIS GRONINGEN
-
| CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
-
| ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
-
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
-
| EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS
-
| LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS
-
| OREBRO UNIVERSITY
-
| REGION HOVEDSTADEN
-
| RESEARCH AND INNOVATION SERVICES DOO ZA USLUGE
-
| UNIVERSITA CATTOLICA DEL SACRO CUORE
-
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
-
| WEIZMANN INSTITUTE OF SCIENCE